Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 2025-08-05
VOLUNTARY ANNOUNCEMENT – IND APPLICATION FOR JSKN022 WAS OFFICIALLY ACCEPTED BY THE CDE 2025-08-03
VOLUNTARY ANNOUNCEMENT – JSKN003 RECEIVED THE U.S. FDA APPROVAL TO INITIATE A PHASE II CLINICAL STUDY IN THE TREATMENT OF PROC NOT RESTRICTED BY HER2 EXPRESSION 2025-07-31
VOLUNTARY ANNOUNCEMENT – JSKN003 FOR THE TREATMENT OF GC/GEJ WAS GRANTED ODD BY THE U.S. FDA 2025-07-29
Next Day Disclosure Return 2025-07-17
VOLUNTARY ANNOUNCEMENT – INCREASE IN SHAREHOLDING BY DIRECTORS AND SENIOR MANAGEMENT AND EXERCISE OF OPTIONS BY A DIRECTOR 2025-07-17
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 2025-07-04
(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND (2) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES 2025-06-30
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025 2025-06-12
INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER 2025-06-06